Advertisement
New Zealand markets open in 1 hour 4 minutes
  • NZX 50

    11,719.82
    +29.62 (+0.25%)
     
  • NZD/USD

    0.6202
    +0.0007 (+0.12%)
     
  • ALL ORDS

    7,899.20
    +33.90 (+0.43%)
     
  • OIL

    76.57
    -2.04 (-2.60%)
     
  • GOLD

    2,045.80
    +15.10 (+0.74%)
     

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of October 31, 2023

PARIS, November 06, 2023--(BUSINESS WIRE)--Regulatory News:

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of October 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

  • Listing Place: Euronext Growth Paris

  • ISIN Code : FR0014005OJ5

  • Web site: acticor-biotech.com

Date

Number of shares making
up the share capital

Theoretical number of
voting rights (1)

Number of voting
rights excluding
shares stripped of
voting rights (2)

October 31, 2023

12.338.781

12.338.781

12.281.995

  1. In accordance with Article 223-111 of the AMF’s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.

  2. The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. The efficacy of glenzocimab is now being analyzed in an international Phase 2/3 study, ACTISAVE, with clinical results expected in Q2 2024.

In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For more information, visit: www.acticor-biotech.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231106612673/en/

Contacts

ACTICOR BIOTECH
Gilles AVENARD, MD
CEO and Founder
gilles.avenard@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD
General Manager and CSO
Sophie.binay@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

NewCap
Mathilde BOHIN / Quentin MASSÉ
Investor Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 94 95

NewCap
Arthur ROUILLÉ
Media Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 00 15